| Literature DB >> 30834140 |
N Siouta1, A Heylen2, B Aertgeerts3, P Clement4, J Van Cleemput5, W Janssens6, J Menten1.
Abstract
BACKGROUND: Patients with chronic heart failure (CHF) and patients with chronic obstructive pulmonary disease (COPD) are amenable to integrated palliative care (PC); however, despite the recommendation by various healthcare organizations, these patients have limited access to integrated PC services. In this study, we present the protocol of a feasibility prospective study that aims to explore if an "early integrated PC" intervention can be performed in an acute setting (cardiology and pulmonology wards) and whether it will have an effect on (i) the satisfaction of care and (ii) the quality of life and the level of symptom control of CHF/COPD patients and their informal caregivers.Entities:
Year: 2019 PMID: 30834140 PMCID: PMC6385452 DOI: 10.1186/s40814-019-0420-y
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1Sequence of the feasibility before-after intervention study
NYHA classification for CHF symptoms
| NYHA class | Symptoms |
|---|---|
| I | Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g., no shortness of breath when walking, climbing stairs, etc. |
| II | Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity |
| III | Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20–100 m) |
| IV | Severe limitations, experiences symptoms even while at rest, mostly bed-bound patients |
NYHA New York Heart Association
GOLD criteria for COPD
| A = low risk, low symptom burden | |
| • Low symptom burden (mMRC of 0–1 or CAT score < 10) and | |
| • FEV1 of 50% or greater (old GOLD 1–2) and low exacerbation rate (0–1/year) | |
| B = low risk, higher symptom burden | |
| • Higher symptom burden (mMRC of 2 or more or CAT of 10 or more) and | |
| • FEV1 of 50% or greater (old GOLD 1–2) and low exacerbation rate (0–1/year) | |
| C = high risk, low symptom burden | |
| • Low symptom burden (mMRCof 0–1 or CAT score < 10) and | |
| • FEV1 < 50% (old GOLD 3–4) and/or high exacerbation rate (2 or more/year) | |
| D = high risk, higher symptom burden | |
| • Higher symptom burden (mMRC of 2 or more or CAT of 10 or more) and | |
| • FEV1 < 50% (old GOLD 3–4) and/or high exacerbation rate (2 or more/year) |
mMRC Modified Medical Research Council Dyspnea Scale, CAT COPD assessment test, FEV1 the amount of air a patient can force from his/her lungs in 1 s
Feasibility assessment of 14 methodological issues
| Methodological issues | Findings | Evidence |
|---|---|---|
| 1. Did the feasibility study allow a sample size calculation for the main trial? | ||
| 2. What factors influenced eligibility and what proportion of those approached were eligible? | ||
| 3. Was recruitment successful? | ||
| 4. Did eligible participants consent? | ||
| 5. Were participants successfully randomized and did randomization yield equality in groups? | ||
| 6. Were blinding procedures adequate? | ||
| 7. Did participants adhere to the intervention? | ||
| 8. Was the intervention acceptable to the participants? | ||
| 9. Was it possible to calculate intervention costs and duration? | ||
| 10. Were outcome assessments completed? | ||
| 11. Were outcomes measured those that were the most appropriate outcomes? | ||
| 12. Was retention to the study good? | ||
| 13. Were the logistics of running a multicenter trial assessed? | ||
| 14. Did all components of the protocol work together? |
Fig. 2Study procedure for patients and their informal caregivers